T-cell prolymphocytic leukaemia in a patient with chronic myeloid leukaemia receiving nilotinib: first documented report

J Clin Pathol. 2019 Jul;72(7):511-512. doi: 10.1136/jclinpath-2019-205799. Epub 2019 Apr 19.
No abstract available

Keywords: chronic myelogenous leukaemia; common progenitor model; nilotinib; t-prolymphocytic leukaemia; tyrosine kinase inhibitor.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Female
  • Humans
  • Immunophenotyping
  • Karyotype
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Leukemia, Prolymphocytic, T-Cell / diagnosis*
  • Leukemia, Prolymphocytic, T-Cell / genetics
  • Leukemia, Prolymphocytic, T-Cell / pathology
  • Middle Aged
  • Philadelphia Chromosome / drug effects*
  • Prognosis
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / adverse effects*
  • Pyrimidines / administration & dosage
  • Pyrimidines / adverse effects*

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Pyrimidines
  • nilotinib